Core Viewpoint - The company has announced the continuation of cash management using idle raised funds, with a maximum amount of RMB 250 million, aimed at improving fund utilization efficiency while ensuring that it does not affect the construction and use of investment projects [1][9]. Investment Overview - Investment Purpose: The objective is to enhance the efficiency of fund utilization without impacting the construction of investment projects, thereby increasing returns for the company and its shareholders [3]. - Investment Amount: The total amount for the entrusted financial management is RMB 250 million [4]. - Source of Funds: The funds are sourced from temporarily idle raised funds [5]. Fundraising Background - The company was approved to publicly issue 40.2 million shares at a price of RMB 63.32 per share, raising a total of RMB 2545.464 million, with a net amount of RMB 2441.1345 million after deducting issuance costs [6]. Investment Types and Management - Investment Type: The company will invest in RMB structured deposits [7]. - Investment Method: The company will use temporarily idle raised funds to purchase cash management products issued by banks, which are characterized by high safety, good liquidity, and a maximum term of 12 months [8]. Recent Financial Management Situation - As of June 30, 2025, the company has invested RMB 2,081.956 million in projects funded by raised funds, with net interest income from the raised funds account amounting to RMB 7.2489 million [8]. Impact on the Company - The maximum amount of idle raised funds for cash management is RMB 250 million, which represents 12.11% of the company's latest cash balance, and is not expected to significantly impact the company's future operations, financial status, or cash flow [12].
甘李药业股份有限公司关于使用闲置募集资金进行现金管理到期赎回并继续进行现金管理的进展公告